Recombinant Human ELAVL3 protein

ELAVL3. also known as HuD, is a member of the Embryonic Lethal Abnormal Vision-like (ELAVL) family of RNA-binding proteins. These proteins are evolutionarily conserved and play critical roles in post-transcriptional gene regulation by binding to AU-rich elements (AREs) or other conserved motifs in the 3' untranslated regions (UTRs) of target mRNAs. ELAVL3 is predominantly expressed in neurons and neuroendocrine cells, where it stabilizes mRNAs, enhances their translation, and regulates RNA splicing or localization. It is particularly implicated in neuronal development, differentiation, and synaptic plasticity, with studies linking it to processes like axon guidance, neurite outgrowth, and long-term memory formation.

Recombinant ELAVL3 protein is engineered for in vitro studies to dissect its molecular interactions and functional mechanisms. Typically produced in bacterial (e.g., *E. coli*) or eukaryotic expression systems, the recombinant protein retains RNA-binding activity and can be purified using affinity tags (e.g., His-tag). Researchers utilize it to investigate RNA-protein binding kinetics, identify target transcripts via RNA immunoprecipitation (RIP) or CLIP-seq, and explore its role in neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s) or neurodevelopmental disorders. Dysregulation of ELAVL3 has been associated with conditions like paraneoplastic neurological syndromes, where autoantibodies against HuD are detected. Its recombinant form also serves as a tool for drug screening aimed at modulating RNA stability or neuroregeneration pathways. Structural studies using recombinant ELAVL3 have revealed conserved domains, including three RNA recognition motifs (RRMs) critical for its function. Overall, recombinant ELAVL3 is a vital resource for unraveling its neurobiological roles and therapeutic potential.